Beta-2 microglobulin in ESRD: an in-depth review

Area of Science:

• Nephrology
• Biochemistry

Background:

• Beta-2 microglobulin (B2M) is a low-molecular-weight protein implicated in end-stage renal disease.
• B2M retention, tissue deposition, fibril aggregation, and glycosylation contribute to dialysis-related amyloidosis (DRA).

Purpose of the Study:

• To investigate the role of beta-2 microglobulin in dialysis-related amyloidosis.
• To explore methods for improving B2M removal during dialysis.
• To assess the impact of dialysis membrane characteristics on patient mortality.

Main Methods:

• Review of studies on beta-2 microglobulin in end-stage renal disease.
• Analysis of factors influencing DRA onset, including membrane type and hemodiafiltration volume.
• Evaluation of adsorptive methods for B2M removal.
• Comparison of mortality risk associated with different dialysis membrane clearances of B2M.

Main Results:

• Noncellulosic membranes, particularly with high-volume hemodiafiltration, may prolong DRA onset.
• Adsorptive techniques show promise for enhancing B2M removal.
• Dialysis membranes with higher B2M clearance appear to be associated with a reduced mortality risk.

Conclusions:

• Effective removal of beta-2 microglobulin is crucial in managing end-stage renal disease and preventing dialysis-related amyloidosis.
• Dialysis membrane selection can influence patient outcomes, including mortality.
• Further research into advanced dialysis techniques and membrane technologies is warranted.